Related Experiment Video

Updated: Jul 19, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

472

Antidiabetic activity of eupafolin through peroxisome proliferator-activated receptor-gamma and PI3K/Akt signaling in

Su Wu1, Wenwei Ai1, Lei Nie2

  • 1Department of General Medicine, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang City, Jiangxi Province, China.

Journal of Biochemical and Molecular Toxicology
|August 11, 2023
PubMed

Insights

Eupafolin, a flavonoid, effectively lowers blood glucose and insulin resistance in Type 2 Diabetes (T2D) rats. It also improves liver antioxidant function and activates key signaling pathways, suggesting potential as an antidiabetic drug.

Area of Science:

  • Pharmacology and Toxicology
  • Endocrinology and Metabolism
  • Biochemistry

Background:

  • Eupafolin is a flavone phyto-compound with known anti-inflammatory, antioxidant, and antiproliferative effects.
  • Type 2 Diabetes (T2D) is a metabolic disorder characterized by insulin resistance and hyperglycemia.
  • Developing novel therapeutic agents for T2D is a significant medical need.

Purpose of the Study:

  • To investigate the antidiabetic effects of eupafolin in a rat model of T2D.
  • To elucidate the molecular mechanisms underlying eupafolin's action in T2D.

Main Methods:

  • Type 2 Diabetes was induced in rats using nicotinamide and streptozotocin (STZ).
  • Eupafolin treatment was administered for 15 days to diabetic rats.
  • Key metabolic parameters, insulin signaling proteins (InsR, IRS-2, GLUT4, PI3K/Akt), and liver oxidative stress markers were assessed.

Main Results:

  • Eupafolin treatment significantly reduced fasting blood glucose (FBG) and improved glucose tolerance.
  • Insulin resistance (IR), assessed by HOMA-IR, was markedly decreased.
  • Eupafolin normalized liver antioxidant enzymes, increased liver glycogen, and upregulated InsR, IRS-2, GLUT4, and PPARγ expression.
  • Activation of the PI3K/Akt signaling pathway was observed.

Conclusions:

  • Eupafolin demonstrates significant antidiabetic properties in a T2D rat model.
  • Its mechanism involves enhancing insulin sensitivity, improving antioxidant capacity, and activating the PPARγ and PI3K/Akt signaling pathways.
  • Eupafolin shows promise as a potential therapeutic agent for Type 2 Diabetes, warranting further clinical investigation.
Keywords:
PI3K/AktPPARγType 2 diabeteseupafolinserum insulin

More Related Videos

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

611
Fixation and Operational Method for Abdominal Massage in T2DM Mice06:00

Fixation and Operational Method for Abdominal Massage in T2DM Mice

Published on: March 7, 2025

238

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.3K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.7K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
234
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.4K